The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …

Alzheimer's disease is defined by the presence of β-amyloid plaques and neurofibrillary tau
tangles potentially preceding clinical symptoms by many years. Previously only detectable …

Since tau PET tracers were introduced, investigators have quantified them using a wide
variety of automated methods. As longitudinal cohort studies acquire second and third time …

Deposition of amyloid and tau pathology can be quantified in vivo using positron emission
tomography (PET). Accurate longitudinal measurements of accumulation from these images …

Purpose To examine associations between the APOE-ε2 and APOE-ε4 alleles and core
Alzheimer's disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau …

Background Neuropathological studies have linked tau aggregates to neuronal loss. To
describe the spatial distribution of neurofibrillary tangle pathology in post-mortem tissue …

[18F] MK-6240 is a second-generation tau PET-tracer to quantify neurofibrillary tangles in-
vivo. However, individually variable levels of meningeal uptake induce spill-in-effects into …

Abstract Purpose In vivo Alzheimer's disease (AD) biomarkers for tau pathology are
cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [18 F] flortaucipir positron emission …

Tau accumulation starts during the preclinical phase of Alzheimer's disease and is closely
associated with cognitive decline. For preventive purposes, it is important to identify factors …

Tau proteins accumulation and their spreading pattern were affected by gender in cognitive
impairment patients, especially in the progression of Alzheimer's disease (AD). However, it …